Massachusetts Institute of Technology

Aerial Coordinator and Camera Pilot for Hollywood Films and TV Kevin LaRosa Becomes Pilot Ambassador for Bose Aviation

Retrieved on: 
Thursday, July 21, 2022
Massachusetts Institute of Technology, Time, A20, GLOBE, Aviation, Aircraft, Bose Corporation, Industry, Larosa, Instagram, Twitter, Foreign relations of Zambia, SWAT, Social media, Research, In Bed with Medinner (series 2), CBS, EAA AirVenture Oshkosh, Top Gun, TSO, EAA, Avenger, Top Gun: Maverick, Devotion, 2000 Australia Beechcraft King Air crash, Music, Senior, Atmosphere, ATP, LinkedIn, SAG, Grey, Engineering, Attention, Sony, Airline, Film, Take Me Home Huey, Facebook, Paramount, Bose

LOS ANGELES, July 21, 2022 (GLOBE NEWSWIRE) -- Today, Kevin LaRosa, aerial coordinator and camera pilot for "Top Gun: Maverick," announced he will be a pilot ambassador for Bose aviation headsets.

Key Points: 
  • LOS ANGELES, July 21, 2022 (GLOBE NEWSWIRE) -- Today, Kevin LaRosa, aerial coordinator and camera pilot for "Top Gun: Maverick," announced he will be a pilot ambassador for Bose aviation headsets.
  • This is a natural next step for me, and I look forward to continuing to wear their headset and supporting Bose at key aviation events in the coming year," said Kevin LaRosa.
  • "Kevin's recent work in Top Gun: Maverick caught our attention, and his resume of other aerial coordination duties speaks for itself.
  • Kevin LaRosa II is a third-generation pilot and second-generation aerial coordinator, and stunt pilot.

Hideaki Takase Appointed to Board of MUFG Americas Holdings Corporation and MUFG Union Bank, N.A., Succeeding Takayoshi Futae

Retrieved on: 
Wednesday, July 20, 2022
MIT Sloan School of Management, MUFG Union Bank, Association, Acquisition, Non-U.S. operators of the M60 Patton, Mitsubishi Bank, Hitotsubashi University, Global, Massachusetts Institute of Technology, PPM America, Inc., Mitsubishi UFJ Financial Group, General manager, Safety, EMEA, Mitsubishi, Global Commercial Credit, Business plan, Leadership, Business administration, Master of Business Administration, MBE, MBA, MUFG Bank, TBK, Head, Public sector banks in India, MUFG, Bank, Management, Economics

NEW YORK, July 20, 2022 /PRNewswire/ -- MUFG, one of the world's leading financial groups, today announced that Hideaki "Hide" Takase has been appointed to the board of directors for MUFG Americas Holdings Corporation and its U.S. banking subsidiary, MUFG Union Bank, N.A., effective August 2, 2022.

Key Points: 
  • NEW YORK, July 20, 2022 /PRNewswire/ -- MUFG, one of the world's leading financial groups, today announced that Hideaki "Hide" Takase has been appointed to the board of directors for MUFG Americas Holdings Corporation and its U.S. banking subsidiary, MUFG Union Bank, N.A., effective August 2, 2022.
  • Mr. Takase succeeds Takayoshi "Taka" Futae, who has been a member of the board of directors since April 2022.
  • "On behalf of my fellow board members, we are pleased that Hide has been appointed to the board of directors," said Toby Myerson, lead independent director.
  • "Taka has been a trusted partner to me and to the board, and we have benefitted tremendously from his leadership and institutional knowledge.

Mesirow's Ben Blakney Named to Savoy 2022 List of Most Influential Black Executives

Retrieved on: 
Wednesday, July 20, 2022
Association, Massachusetts Institute of Technology, Corporation, RIA, Blakney, Investment banking, Corporate America, Industry, Real estate, Woman, SEC, Certified Information Systems Security Professional, Culture, Mesirow Financial, Capital market, Savoy, The Last Best Place, National Association, City, Institutional Investor Advisory Services, Multimedia, Circularity, Urban planning, Barron's, Leadership, Quality of life, Unemployment, LinkedIn, Equity, Williams College, Crain's Chicago Business, Man, Growth, Risk, II, LINK, Population, Management

CHICAGO, July 20, 2022 /PRNewswire/ -- Mesirow, an independent, employee-owned financial services firm, today announced Ben Blakney , President of Mesirow Institutional Real Estate Direct Investments ("IRED"), was named one of Savoy Magazine's 2022 Most Influential Black Executives in Corporate America.

Key Points: 
  • CHICAGO, July 20, 2022 /PRNewswire/ -- Mesirow, an independent, employee-owned financial services firm, today announced Ben Blakney , President of Mesirow Institutional Real Estate Direct Investments ("IRED"), was named one of Savoy Magazine's 2022 Most Influential Black Executives in Corporate America.
  • Savoy, one of the leading African American business and lifestyle magazines, published its definitive list of African American executives, influencers and achievers impacting corporate America in its summer issue.
  • Ben has more than 30 years of investment industry experience as a senior executive in both the public and private sectors.
  • "I am honored to be recognized by Savoy and humbled for being included in the publication's prestigious list of Black Executives," said Blakney.

Navitus Health Solutions Welcomes Shayna Schulz as Chief Operations Officer

Retrieved on: 
Wednesday, July 20, 2022
Insurance, Pharmaceutical, Health, Data Management, Health Technology, Professional Services, Technology, Health Insurance, Blue Shield, Insurance, Customer service, Twitter, Boston University, SSM Health, Massachusetts Institute of Technology, CEO, Literature, Allstate, Health, Pharmacy, Multimedia, PBM, News, Philosophy, Business administration, Prescription, Master of Business Administration, Senior, LinkedIn, Transformation, Life, Efficiency, Costco, Pharmaceutical industry, Management, Music, Navitus Bay wind farm

Navitus Health Solutions , an industry-disrupting pharmacy benefit manager (PBM) thats committed to bringing humanity to pharmacy benefits management through greater transparency and affordability, announced today that Shayna Schulz has joined the company as Chief Operations Officer.

Key Points: 
  • Navitus Health Solutions , an industry-disrupting pharmacy benefit manager (PBM) thats committed to bringing humanity to pharmacy benefits management through greater transparency and affordability, announced today that Shayna Schulz has joined the company as Chief Operations Officer.
  • Shayna most recently served as Chief Operating Officer for Included Health.
  • Navitus Health Solutions, owned by SSM Health and Costco Wholesale Corporation, is a disruptive industry alternative to traditional pharmacy benefit manager (PBM) models.
  • By returning 100% of rebates and discounts received and deploying a lowest-net-cost philosophy, Navitus helps reduce costs and improve member health.

Provectus Biopharmaceuticals Establishes Research Collaboration with University of Nevada, Las Vegas to Investigate Small Molecule Immunotherapy Rose Bengal for Tissue Regeneration and Repair

Retrieved on: 
Tuesday, July 19, 2022
Research, SEC, University, Regeneration, IL, Epson HX-20, National, Dermatology, OTCQB, Microbiology, RBS, Security (finance), Massachusetts Institute of Technology, P.O, Publication, The New York Times, U.S. Securities and Exchange Commission, Safety, Book, Tseng Labs, NIH, Drug discovery, GLOBE, Forward-looking statement, School, African clawed frog, Technology, Ophthalmology, Wound healing, HX, Harvard University, Hematology, Legislation, Virology, UNLV, Hospital, Role, Associate, Howard Hughes Medical Institute, Boston Children's Hospital, Pathology, Company, Immunotherapy, Cell death, Vertebrate, School of Life Sciences (University of Dundee), Doctor of Philosophy, Reno 1868 FC, Xanthene, Pharmaceutical industry, Science, Biology, Molecular biology, Xenopus

RBS is the lead member of a class of small molecules called halogenated xanthenes that is entirely owned by Provectus.

Key Points: 
  • RBS is the lead member of a class of small molecules called halogenated xanthenes that is entirely owned by Provectus.
  • Dr. Tseng is an expert in tissue regeneration and a leader in the regenerative biology and bioelectrical signaling fields.
  • Dr. Tseng has identified key factors that control limb and eye regeneration, and has also established a new model for studying embryonic eye stem cells.
  • Recent medical journal publications of hers include From Cell Death to Regeneration: Rebuilding After Injury (Front Cell Dev Biol 18;9:655048.

Terran Orbital Successfully Completes Next Step in Demonstrating Space-to-Ground Optical Link on NASA’s Pathfinder Technology Demonstrator 3 Satellite

Retrieved on: 
Tuesday, July 19, 2022
Technology, Other Defense, Engineering, Satellite, Other Technology, Military, Aerospace, Manufacturing, Hardware, Defense, GNC, Acquisition, Launch and Early Orbit phase, LEO, Solution, Massachusetts Institute of Technology, CubeSat, NYSE, LEOP, Spacecraft, Technology, NASA, Credit, Orbital Corporation, Orbital, Algorithm, Byte, Navigation, SpaceX, LLAP, Pathfinder Technology Demonstrator, Communications satellite, Alliance, Launch

Acquisition of the Lasercom Optical Link means that the spacecraft and the optical ground terminal have successfully exchanged laser communication signals bringing PTD-3 one step closer to full payload commissioning.

Key Points: 
  • Acquisition of the Lasercom Optical Link means that the spacecraft and the optical ground terminal have successfully exchanged laser communication signals bringing PTD-3 one step closer to full payload commissioning.
  • The mission series, managed by NASAs Small Spacecraft Technology program within the agencys Space Technology Mission Directorate, demonstrates novel CubeSat technologies in Low-Earth Orbit (LEO).
  • Following Terran Orbitals completion of the commissioning process for the PTD-3 spacecraft, the TBIRD payload will demonstrate an astonishing 200-Gbps space-to-ground optical link.
  • Terran Orbital has been privileged to be involved with PTD-3 since its inception, said Terran Orbital Co-Founder, Chairman, and Chief Executive Officer Marc Bell.

DermTech Appoints Two New Board Members

Retrieved on: 
Monday, July 18, 2022
Biotechnology, General Health, Health, Genetics, Oncology, Boston University, Illumina, Inc., Medicare, SEC, Leadership, University, Eli Lilly and Company, Dermatology, Skin, Cancer, Patient, Security (finance), Solution, U.S. Securities and Exchange Commission, Chemical engineering, Inflammation, Massachusetts Institute of Technology, Private Securities Litigation Reform Act, Northeastern University, Genomics, Adoption, Genetics, LLC, Pennsylvania State University, NASDAQ, Precision medicine, Medicine, NanoString Technologies, List of life sciences, Myriad Genetics, Company, Eli Lilly, Annual report, Smart, Abcam, Management, Pharmaceutical industry, Medical imaging, Biology, Technology, Illumina

These appointments expand DermTechs board of directors to eight members.

Key Points: 
  • These appointments expand DermTechs board of directors to eight members.
  • Their perspectives in guiding high-growth companies will provide our board with valuable insights as we look ahead to important operating milestones.
  • I am honored to join the board and support DermTechs mission to improve the lives of millions with individualized care.
  • Most of these factors are outside of the control of DermTech and are difficult to predict.

Invitae Announces Leadership Transition

Retrieved on: 
Monday, July 18, 2022
Leadership, University, History, M.B.A, CEO, Patient, Security (finance), Massachusetts Institute of Technology, Doctor of Philosophy, Caterpillar Inc., General Motors, Electrical engineering, Caterpillar, Time, Georgia Institute of Technology College of Computing, U.S. Securities and Exchange Commission, Engineering, Private Securities Litigation Reform Act, Forward-looking statement, NYSE, Genomics, Heart, Genetic testing, Transport, Amazon (company), Board of directors, Genomic Health, Board, Industry, Medicine, Efficiency, Growth, COO, Emporia State University, Management, Amazon, Technology, Biochemistry, Chemistry, Invitae, Director

SAN FRANCISCO, July 18, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced executive leadership and Board changes to help ensure the company realizes the full potential of its industry-leading genetics testing platform and delivers tangible and sustainable value for stockholders. Specifically, Kenneth D. Knight, who has served as Invitae's chief operating officer since 2020, is succeeding Sean George, Ph.D., as CEO and is joining the Board of Directors. Additionally, Randy Scott, Ph.D., Invitae's co-founder, former CEO from 2012 to 2017, and former executive chairman from 2017 to 2019, is returning to the company as chairman of the Board. Eric Aguiar, who has served as Invitae's independent chairman since 2019 and a member of the Board since 2010, is now serving as lead independent director. The changes are effective immediately.

Key Points: 
  • Dr. George, co-founder and CEO of Invitae since 2017, will serve as a consultant to the company through a transition period and will retain his role as a member of the Invitae Board.
  • The company will unquestionably benefit from his leadership as CEO, his deep understanding of Invitae and its growth drivers and his commitment to securing a successful, sustainable operating platform for the long term.
  • "At the same time, Randy's return as chairman will allow Invitae to continue to benefit from cutting-edge science, deep industry leadership and unparalleled institutional knowledge," Dr. Aguiar continued.
  • "With the timing now right for this transition, I am honored to pass the baton to Ken and look forward to continuing to support Invitae at the Board level.

Nuvation Bio Appoints David Liu, M.D., Ph.D., as Chief Medical Officer and Kerry Wentworth as Chief Regulatory Officer

Retrieved on: 
Monday, July 18, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, Research, Medivation, University, Global, Agenus, Cancer, Patient, Rituximab, Massachusetts Institute of Technology, Osteoarthritis, Flexion Therapeutics, Peking University Health Science Center, NYSE, Indolent lymphoma, New Drug Application, Degenerative disease, Regulatory affairs, NUVB, Nivolumab, Pain management, Medical school, Genzyme, Bristol Myers Squibb, Ipilimumab, Company, NDA, Pharmacovigilance, Biostatistics, Celgene, Data management, Therapy, Prostate cancer, Peking University School of Transnational Law, Quality, Translational research, Pharmaceutical industry, Medical device

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of David Liu, M.D., Ph.D., as Chief Medical Officer and Kerry Wentworth as Chief Regulatory Officer.

Key Points: 
  • Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of David Liu, M.D., Ph.D., as Chief Medical Officer and Kerry Wentworth as Chief Regulatory Officer.
  • I am honored to join Nuvation Bio and oversee the clinical development of innovative therapies for the most difficult-to-treat cancers, said Dr. Liu.
  • Nuvation Bios mission to bring meaningful cancer treatments to patients who have nearly exhausted all options deeply resonates with me, said Ms. Wentworth.
  • Most recently, Dr. Liu served as the Chief Medical Officer at a biotechnology company based in Shanghai, China.

'Sony Research Award Program' Now Accepting Submissions Focused on Emerging and Innovative Technological Development

Retrieved on: 
Friday, July 15, 2022
Research, Feedback, University, Massachusetts Institute of Technology, Machine learning, Korea Carbon Capture & Sequestration R&D Center, Program, University of California, San Diego, Biomedicine, Technology transfer, University of Wisconsin–Madison, Information technology, List of life sciences, Senior, Faculty, R, Television, Pharmaceutical industry, Medicine, Sony, Technology

TOKYO, July 15, 2022 /PRNewswire/ -- Sony Group Corporation (Sony) announced today that it is now accepting submissions for its Sony Research Award Program, currently in its seventh year. The program provides funding for projects researching emerging and innovative technologies in collaboration with Sony's own research groups, and is open to universities and, starting this year, to other research institutions such as government research institutes and nonprofit organizations. The program is offered in the U.S., Canada, 17 European countries*1 and India.

Key Points: 
  • TOKYO, July 15, 2022 /PRNewswire/ -- Sony Group Corporation (Sony) announced today that it is now accepting submissions for its Sony Research Award Program, currently in its seventh year.
  • The program provides funding for projects researching emerging and innovative technologies in collaboration with Sony's own research groups, and is open to universities and, starting this year, to other research institutions such as government research institutes and nonprofit organizations.
  • The Sony Research Award Program is comprised of two awards the Faculty Innovation Award and the Focused Research Award.
  • The Focused Research Award provides support for up to $150,000 USD for one year*2, to conduct research more focused in the areas of Sony's immediate interest.